Study of fruquintinib, tislelizumab, and radiation for esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two drugs (fruquintinib and tislelizumab) followed by radiation therapy for people with advanced esophageal squamous cell carcinoma. The goal is to see if this approach can help shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of esophageal squamous cell carcinoma that has not spread to distant organs.
- Your tumor must be measurable on a CT or MRI scan (at least 1 cm in size).
- You must not have received radiation to the chest or immunotherapy before.
- Your blood counts, liver, kidney, heart, and lung function must be within certain limits.
- You must be willing to stop other cancer treatments for at least 4 weeks before starting the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of drugs — fruquintinib plus paclitaxel liposome plus nidaplatin — as a first treatment for people with advanced esophageal squamous cell carcinoma that has spread. It aims to see if this combination can help control the cancer better than standard treatments.
This trial tests a short course of radiation combined with two drugs (raltitrexed and tislelizumab) for people with esophageal cancer that has returned after standard treatment. The goal is to see if these combinations can shrink tumors and improve survival.
This study tests whether adding tislelizumab to chemotherapy or radiation can work better for older adults with advanced or recurrent/metastatic esophageal squamous cell cancer. The goal is to slow the cancer down and improve control of the disease.
This trial tests if adding the immunotherapy drug tislelizumab to standard chemotherapy before surgery or radiation can improve outcomes for people with resectable esophageal squamous cell carcinoma. It is designed for patients whose cancer is in the chest and has not spread to distant organs.
This trial tests a combination of chemotherapy and immunotherapy followed by targeted radiation before surgery for a specific type of esophageal cancer (T3N+). It aims to see if this approach can improve outcomes for patients whose tumors have not yet spread to other organs.
This trial tests a combination of fruquintinib (a pill that blocks blood vessel growth), sintilimab (an immunotherapy), and targeted radiation for people with stomach or GEJ cancer that has only a few new spots after at least one prior treatment. The goal is to see if this triple approach helps control the cancer better than standard options.
Hear when a new Esophageal Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.